The deal size was increased to $90M in common stock from $75M in common stock. Goldman Sachs, Leerink, Stifel, RBC Capital and William Blair acted as joint book running managers for the offering.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Contineum Therapeutics Submits Phase 2 Trial for PIPE-791
- Contineum offers to sell $75M in common stock
- Contineum price target lowered to $14 from $16 at Baird
- Contineum price target lowered to $22 from $25 at RBC Capital
- Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback